Hemoglobin A1C (HbA1c)
Also known as: HbA1c
HbA1c reflects average blood glucose over roughly the prior 90 days. It is the standard biomarker for diabetes screening, prediabetes identification, and glycemic-control monitoring.
What Hemoglobin A1C measures
Hemoglobin A1C (HbA1c) reflects the percentage of hemoglobin glycated by glucose, integrating average blood glucose over the prior ~3 months. It is the standard marker of long-term glycemic trend.
Clinical significance
A1C is the most widely used metabolic marker but lags upstream signals (fasting insulin, postprandial glucose). It is best interpreted alongside fasting insulin to detect insulin resistance before A1C drifts, and alongside CBC to rule out hemoglobinopathies that distort the value.
How oMeds reviews it
A1C is reviewed as a cumulative marker in optimization — never in isolation. Provider review pairs A1C with fasting insulin, glucose, lipids, ApoB, and hs-CRP. A1C alone misses the resistance phase by years.
Standard clinical reference intervals
Lab-reported reference ranges from established standards bodies. These are diagnostic thresholds — they do not represent optimization targets.
Source: ADA Standards of Care 2024 (normal <5.7%; prediabetes 5.7-6.4%; diabetes ≥6.5%)
oMeds optimization targets
Editorial bands that inform provider-reviewed conversations. These are wellness targets, not diagnostic thresholds.
Provider-reviewed wellness targets the lower portion of the normal A1C range where cardiometabolic risk is lowest, contextualized by insulin and lipid markers.
oMeds optimization ranges are editorial targets that inform conversations with a licensed provider. They are NOT diagnostic thresholds and do not replace lab reference ranges.
Hemoglobin A1C — frequently asked
Why is A1C normal but I have symptoms?
A1C lags. Fasting insulin and HOMA-IR detect insulin resistance years before A1C moves. Provider review adds these markers when symptoms suggest metabolic dysregulation despite a normal A1C.
What distorts A1C?
Anemia, hemoglobinopathies, recent blood loss or transfusion, kidney disease, and certain medications can all skew A1C. Provider review pairs it with CBC and clinical context.
Source literature
- ADA Standards of Care 2024 · Diabetes Care
- Limitations of A1C testing (Sacks) · Clinical Chemistry
How this entity relates
Every entity in the oMeds knowledge graph cross-links to the conditions, biomarkers, medications, and educational surfaces it touches.
Conditions this biomarker informs
- Metabolic Syndrome
- Insulin Resistance
- Obesity
- Erectile Dysfunction
- Type 2 Diabetes
- Prediabetes
- Non-Alcoholic Fatty Liver Disease (NAFLD)
- Obstructive Sleep Apnea
- Atherosclerotic Cardiovascular Disease
- Cushing Syndrome
- Hormonal Acne
- Metabolic Dysfunction-Associated Steatohepatitis
- Hypertriglyceridemia
- Mild Cognitive Impairment
- Leptin Resistance
Co-reviewed biomarkers
Explore Related Biomarkers
Related Optimization Resources
Recommended Next Step
Take the Universal AssessmentBring this entity into your optimization pathway
Every condition, symptom, biomarker, and medication on oMeds is reviewed by a licensed provider and recalibrated against the standardized biomarker panel.